A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation

Administered By

Awarded By

Contributors

Start/End

  • August 1, 2016 - October 10, 2018